Scientists

Scientists

For science to make the news in a rigorous and attractive way, good sources are needed. Because access to scientific knowledge is a citizen's right.

¿Qué me ofrece?

Help science make headlines with rigour and context. We’ll ask you for feedback on current events in your field and you can participate in the briefings we’ll organise. Need to prepare for an interview? Use our resources on science communication.

Icono
Cómo trabajamos

We’re on the lookout for controversial information about science and we will contact you for your analysis in your area. Do you want to be part of our sources? Contact us. We will not pass your contact details on to anyone else. You can find out more about how we work here.   

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

What is the status of Hipra's Spanish anticovid vaccine?

The European Medicines Agency (EMA) is still considering the approval of Hipra's SARS-CoV-2 vaccine. In mid-May, Hipra said it was ready to "have the vaccine available in a few days" following EMA approval, which it expected by the middle of this year, but which is being delayed until at least after July, as Elia Torroella, Hipra's R&D and Registration Director, explained at a breakfast briefing organised by the company today. 

One more chapter in the never-ending story of wildfires

Our landscapes urgently need proactive, adaptive, integrative management to enable rural development that is compatible in the medium and long term with biodiversity and ecosystem services. It is clear that unilateral and reactive management in the face of the challenges of global change is neither effective nor intelligent. And inaction is also a decision.

1

Reactions: birds lose morphological diversity due to climate change

Climate change is causing a mass extinction of species, but for birds, this loss of biodiversity has wider implications. In research published in the journal Current Biology, researchers use statistical models to predict that this extinction will decrease morphological diversity among the remaining birds at a faster rate than species loss alone.

Reaction to a new intranasal HIV and SARS-CoV-2 vaccination device tested in animals

US researchers have designed an intranasal vaccination device that is capable of delivering immunising proteins through the mucosal surface. The research, published in Science Translational Medicine, shows that strong antibody responses against viruses such as HIV and SARS-CoV-2 have been achieved in mice and non-human primates.